Simulations Plus Overview

  • Founded
  • 1996

  • Status
  • Public

  • Employees
  • 146

  • Stock Symbol
  • SLP

Stock Symbol
  • Investments
  • 5

  • Share Price
  • $65.61

  • (As of Monday Closing)

Simulations Plus General Information


Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Simulations Plus, Inc; Cognigen Corporation; DILIsym, and Lixoft. It generates maximum revenue from Simulations Plus, Inc segment. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) Predictor which is a computer program that takes molecular structures as inputs; MedChem Designer and MedChem Studio.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Other Healthcare Technology Systems
Other Industries
Multimedia and Design Software
Other Healthcare Services
Stock Exchange
Primary Office
  • 42505 Tenth Street West
  • Lancaster, CA 93534
  • United States
+1 (661) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Simulations Plus Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$65.61 $66.88 $35.18 - $67.59 $1.33B 20.2M 129K $0.59

Simulations Plus Financials Summary

In Thousands,
TTM 31-May-2022 FY 2021 31-Aug-2021 FY 2020 31-Aug-2020 FY 2019 31-Aug-2019
EV 862,154 773,535 1,179,956 622,754
Revenue 52,013 46,466 41,589 33,970
EBITDA 17,727 14,496 14,319 13,272
Net Income 11,827 9,782 9,332 8,583
Total Assets 186,223 179,978 168,422 45,197
Total Debt 1,528 1,278 926 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Simulations Plus Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Simulations Plus‘s full profile, request access.

Request a free trial

Simulations Plus Patents

Simulations Plus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-6625585-B1 Method and system for artificial intelligence directed lead discovery though multi-domain agglomerative clustering Expired - Fee Related 18-Feb-2000 000000000 0

Simulations Plus Executive Team (8)

Name Title Board Seat Contact Info
Shawn O'Connor Chief Executive Officer
Will Frederick Chief Financial Officer
Viera Lukacova Chief Scientific Officer
Joshua Fohey Vice President, Business Development
You’re viewing 4 of 8 executive team members. Get the full list »

Simulations Plus Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Simulations Plus Acquisitions (5)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 01-Apr-2020 0000000000 000.00 Drug Discovery 00000 0'0
0000000 00000 01-Jun-2017 0000000000 000.00 Decision/Risk Analysis 0000 0000
00000000 0000 02-Sep-2014 0000000000 000 Other Pharmaceuticals and Biotechnology 0000 0000
000000000 04-Nov-2005 0000000000 00000 Business/Productivity Software 0000 0000
Sage Informatics 31-Aug-2005 Merger/Acquisition Business/Productivity Software 0000 0000
To view Simulations Plus’s complete acquisitions history, request access »

Simulations Plus Subsidiaries (1)

Company Name Industry Location Founded
000000 Drug Discovery Antony, France
To view Simulations Plus’s complete subsidiaries history, request access »